1 / 27

Literature Review

Literature Review. Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado 80045. Targonwnik LE 1 , Bolton JM 2 , Metge CJ 3 , Leung S 1 , Sareen J 2,4.

newman
Download Presentation

Literature Review

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Literature Review Peter R. McNally, DO, FACP, FACG University Colorado Denver School of Medicine Center for Human Simulation Aurora, Colorado 80045

  2. Targonwnik LE1, Bolton JM2, Metge CJ3, Leung S1, Sareen J2,4. 1 Section of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 2 Department of Psychiatry, University of Manitoba, Canada; 3 Department of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada; 4 Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, R3E3P4, Canada. Selective Serotonin Reuptake Inhibitors Are Associated With a Modest Increase in the Risk of Upper Gastrointestinal Bleeding (UGIB). Am J Gastroenterol. 2009;104:1475-1482.

  3. Introduction • Antidepressants are among the most extensively prescribed medications in the US. • The serotonin-specific reuptake inhibitors (SSRIs) are effective for the treatment of depression and general anxiety disorders. • Generally, SSRI’s are considered safer and exhibit a better side effect profile than previous generations of antidepressants. • For these reasons the SSRIs have become one of the most commonly prescribed class of antidepressants. MacGillivray S, et al. Br. Med Journal. 2003;326:1014-17. Gerretsen P, et al. Expert Opin Drug Metab Toxicol. 2008;4:1465-78. Jones CA, et al. Neuropharmacol. 2008;55:1056-65.

  4. Introduction • Accumulation of case reports and meta-analysis have suggested and increased risk for UGI bleeding complications among chronic users of SSRIs. • SSRI’s inhibition of serotonin uptake in platelets is believed to impair the normal haemostatic mechanism, thereby predisposing chronic users of SSRI’s to UGI bleeding. • Factors that predispose to gastric and duodenal ulcers include: H. pylori, ASA, NSAID’s, smoking, alcohol, acid hypersecretion, age > 65 yrs, and COPD. Paton C, et al. Br M J. 2005;331:529-530. Turner MS, et al. J Intern Med.2007;261 :205-213. LiN, et al. Blood Coagul Fibrinol 1997;8:517-23. Malfertheiner P, et al. Lancet. 2009;374:1449-61.

  5. Factors Influencing Platelet Activation & Adhesion Serotonin ADP Thromboxane A2 Platelet Activation Plasmin Collagen Thrombin receptors Epinephrine PAR-4 & PAR-1 Platelet-Activating Factor

  6. Drugs Known to Inhibit Platelet Activation and Adhesion SSRI’s (via) Serotonin Clopidogrel (via) ADP Platelet Inhibition Aspirin (via) Thromboxane A2

  7. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Aim The authors sought to determine: • The risk of adverse upper gastrointestinal outcomes with the use of SSRIs. • The combined risk of adverse upper gastrointestinal outcomes with SSRIs and NSAIDs. • Whether PPIs have a role in lowering risk of GI complications in susceptible individuals on SSRIs and NSAIDs.

  8. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Design: Methods Retrospective review of the Manitoba Population “Health Research Data Repository” • Cohort all Manitoba citizens > 18 yrs continuous enrollment in the health care plan • Study Time Interval April 1995 to March 2007 • Cases included all admitted to hospital with diagnosis of UGI bleeding • Included only UGIB admitted for > 24 hr • Excluded variceal bleeding

  9. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Design: Methods Case Control Group (Each Subject Matched) • Admission date for non UGIB • Age + 3 yrs • Gender • Overall medical co-morbidity*(Johns Hopkins Adjusted Diagnostic Group score *Starfield B, et al. Health Serv Res.1991;26:53-74)

  10. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Design: Methods Determinants of Rx Exposure: SSRIs, NSAIDs, & PPIs • Calculation from Rx initial to next dispensed did not fall below 0.7 standard doses per day. • SSRI included list of Anatomical Therapeutic Chemical Classification System (ACT) Class N06B plus Venlafaxine – see table. • Exposure considered if medication used on or within 14-days of the date of hospital admission. • NSAID included non-selective NSAID or COX-2 inhibitors.

  11. Anatomical Therapeutic Chemical Classification (ATC) Class NO6AB • N06AB Selective serotonin reuptake inhibitors N06AB02 Zimelidine N06AB03 Fluoxetine N06AB04 Citalopram N06AB05 Paroxetine N06AB06 Sertraline N06AB07 Alaproclate N06AB08 Fluvoxamine N06AB09 Etoperidone N06AB10 Escitalopram • Plus Serotonin-norepnephrine reuptake inhibitor N06AX16 Venlafaxine

  12. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Design: Methods Assessment of confounding variables • Comorbid Illness matched by • Johns Hopkins Aggregate Diagnostic Group • Tracking Use of Other medications • Warfarin • Corticosteroids • Clopidogrel • H2-receptor antagonists • Unable to track OTC aspirin use • History of GI disease • Adjusted for GI care or EGD within 6 mo of index date

  13. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Design: Methods Statistics: • Univariate analysis using χ² or Fisher exact test. • Conditional multivariate logistic regression performed to identify independent variables. • Regression analysis using SSRI as reference group to examine combined effects of PPIs and NSAIDs on SSRI users. • Sub-analysis for sex, age, co-medications and co-morbidities.

  14. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Results: • 910,346 subjects from Manitoba, Canada • All > 18 yrs • Manitoba Health Research Data Repository • 1,552 subjects had UGIB • 68,590 Matched Controls no UGIB

  15. Characteristics of Subjects With UGIB vs. Matched Controls Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  16. Characteristics of Subjects With UGIB vs. Matched Controls Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  17. Results of Multi-Conditional Logistic Regression Analysis Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  18. Results of Multi-Conditional Logistic Regression Analysis Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  19. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Results: • SSRI use = 1.38 x ↑ risk for UGIB • SSRI use = 1.43 x ↑ risk for UGIB • when adjusted for confounding variables • SSRI + NSAID = 3.17 x ↑ risk for UGIB • SSRI + NSAID ~ NSAID risk for UGIB • No ∆ in risk for UGIB by duration SSRI use • SSRI + PPI = >60% ↓ risk for UGIB

  20. Duration of SSRI Use (Days) and Odds of UGIB Adjusted Odds Ratio 1.50 1.43 1.33 Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  21. Adjusted Odds Ratio for SSRIs & NSAIDs risk for UGIB and PPI Risk Reduction for UGIB ↓ 61% risk p = 0.056 ↓ 67% risk p = 0.001 ↓ 61% risk p = 0.036 Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482.

  22. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Conclusions • SSRI use is associated with a modest ↑ risk UGIB (1.38X). • The risk of UGIB is increased by co-morbid diseases and concomitant use of NSAIDs. • The risk for UGIB related to SSRI occurs within the first 30 days and risk is not increased further by prolonged use.

  23. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Summary • PPI Rx decreases SSRI UGIB risk • PPI + Any Study Rx Decreases risk for UGIB • SSRI + PPI = ↓ 61% UGIB • NSAID + PPI = ↓ 67% UGIB • SSRI + NSAID + PPI = ↓ 61% UGIB

  24. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Study Summary • This retrospective nested Case control study clearly shows that SSRIs are associated with increase risk for UGIB. • The risk for UGIB from SSRI is equivalent to Warfarin and Clopidogrel, but less than NSAIDs alone. • The co-administration of PPI greatly decreases the risk for UGIB (>60%) for SSRI, NSAID and SSRI + NSAID. • Co-morbid factors that accentuate SSRI UGIB risk include: • Hepatic disease • Renal disease • Alcohol abuse

  25. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Reviewer Comments Targonwnik, et al, fail answer the following questions? • Should selected patients on chronic SSRIs receive co-administration of a PPI to prevent UGIB? • Should patients on SSRI plus other drugs (ASA, NSAIDs, Warfarin, & Clopidogrel) known to increase risk of UGIB be considered for prophylactic PPI?

  26. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Reviewer Comments • Should all patients needing SSRI, be evaluated for infection with H. pylori as is a treatable and modifiable risk factor for ulcer and UGIB? • Should patients needing SSRI, be screened for co-morbidities (Hepatic > Alcoholism > Renal > Schizophrenia > UGI Disease > Cardiovascular disease) also linked to UGIB risk?

  27. Targonwnik LE, et al. Am J Gastroenterol. 104;1475-1482. Reviewer Conclusions • The clinician is urged to remember that SSRIs are used with increasing frequency among the elderly for depression. This select group of the population is already at ↑ risk of PUD: • Other Rx: ASA, NSAID’s, Clopidogrel, & Warfarin • Co-morbid illness: Hepatic, Renal, Cardiovasc & alcoholism • H. pylori infection • We should be mindful of these cumulative risks and offer our elderly patients on SSRIs counter measures to avert UGIB, i.e., treatment of H pylori, avoid ulcerogenic Rx, & PPI prophylaxis for those at high risk.

More Related